Studies
Anokion/Pfizer KAN-101-02 Celiac
Internal Medicine
Gastroenterology
Digestive Disease
Adult Subjects
This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).